Defining patient risks from expanded preventive therapies (Q33945562)

30 July 2017

1 reference

title

Defining patient risks from expanded preventive therapies (English)

1 reference

30 July 2017

1 reference

K G Tolman

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

American Journal of Cardiology

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

issue

12A

1 reference

30 July 2017

page(s)

15E-9E

1 reference

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Preclinical evaluation of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel Bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Association of nonalcoholic fatty liver disease with insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Hepatotoxicity of herbal remedies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900946-2

10.1016/S0002-9149(00)00946-2

7 January 2021

Identifiers

DOI

1 reference

release_qvu62qdpvjeqxm2xitudbw54yu

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qvu62qdpvjeqxm2xitudbw54yu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference